INFRAC enters the final stretch of September with its most distinctive feature unchanged: every insider transaction on record is a buy, and that streak extended again this week.
The boardroom accumulation pattern at Infracore is the story that matters here. A non-executive director added 1,000 shares at CHF 48.90 on September 21, the most recent in a run of purchases that stretches back to late July. Senior management has also been active, with three separate buy transactions logged between September 8 and September 11. Combined, the 90-day net tally runs to 16,060 shares worth roughly CHF 826,000 — and not one sale has appeared in the dataset over that period. The trades are modest in absolute terms, but the consistency across both executive and non-executive ranks is the signal worth noting.
The lending market is calm but has shown a flicker of activity. Availability is extraordinarily loose — more than 8,000% of short interest is currently available to borrow, meaning there is essentially no constraint on new short positions — so the borrow cost jump this week is worth contextualising carefully. Cost to borrow has risen 67% to 5.4%, but that follows a brief dip on September 23 and returns it to roughly where it was on September 21 and 22. The real reference point is mid-July, when borrow costs briefly spiked above 30% before collapsing back. The current level is a fraction of that episode. Short interest itself remains negligible at well under 1% of free float, and the ORTEX short score has edged up only modestly this week to 30.5 — not a level that signals meaningful bearish conviction.
The ownership structure reinforces how tightly held this stock is. Medical Properties Trust holds 53% of shares and M.R.S.I. Medical Research holds a further 23%, leaving a very thin public float. That concentration explains both the sporadic borrow cost volatility and the outsized significance of even small insider purchases: in a stock this illiquid, 1,000 shares from a board member represents real money relative to what trades freely. The sole analyst covering the stock carries a hold rating as of mid-September, though that view is now approaching the edge of freshness.
The stock has added 1.6% on the week to CHF 49.35, recovering part of a modest one-month slide. The next hard date on the calendar is November 27, when Infracore is scheduled to report results. The last earnings print in August produced a 1.9% one-day move and a 3.9% five-day drift — a muted reaction that reflects how few active participants there are in this name. Whether the insider buying cluster ahead of that November date broadens or stalls is the cleanest thing to watch between now and then.
See the live data behind this article on ORTEX.
Open INFRAC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
